Lokelma Dosage & Drug Information

Concise Prescribing Info Bahasa Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Na zirconium cyclosilicate

Indications/Uses

Hyperkalaemia in adults.

Click to view Lokelma detailed prescribing information

Dosage/Direction for Use

Correction phase Adult & elderly Recommended starting dose: 10 g 3 times daily. Patient still hyperkalaemic after 48 hr Continue same regimen for an additional 24 hr. Maintenance phase Recommended starting dose: 5 g once daily w/ possible titration up to 10 g once daily or down to 5 g once every other day as needed. Max: 10 g once daily. Patient on chronic haemodialysis Recommended starting dose: 5 g once daily (non-dialysis days). May be titrated up or down wkly based on pre-dialysis serum K value after long inter-dialytic interval; may adjust dose at intervals of 1 wk in increments of 5-15 g once daily (non-dialysis days).

Click to view Lokelma detailed prescribing information

Overdosage

View Lokelma overdosage for action to be taken in the event of an overdose.

Administration

May be taken with or without food.

Contraindications

Hypersensitivity.

Click to view Lokelma detailed prescribing information

Special Precautions

Discontinue use & re-evaluate patients w/ severe hypokalemia. Not to be used as an emergency treatment for life-threatening hyperkalemia due to its delayed onset of action. Monitor serum K levels; signs & symptoms related to intestinal perforation. Risk of hypokalaemia. Possible QT interval lengthening. Na zirconium cyclosilicate may be opaque to X-rays. Contains Na approx 400 mg/5 g dose. Patients w/ serum K conc >6.5 mmol/L. Long-term (>1 yr) exposure. Avoid use during pregnancy. Childn & adolescents <18 yr.

Click to view Lokelma detailed prescribing information

Use In Pregnancy & Lactation

Click to view Lokelma detailed prescribing information

Adverse Reactions

Hypokalaemia; oedema-related events (including fluid overload & retention; generalised, localised & peripheral oedema; hypervolaemia; peripheral swelling).

Click to view Lokelma detailed prescribing information

Drug Interactions

May transiently increase gastric pH; administer at least 2 hr before or after oral medications w/ clinically meaningful gastric pH dependent bioavailability eg, azole antifungals (ketoconazole, itraconazole, posaconazole), anti-HIV drugs (atazanavir, nelfinavir, indinavir, ritonavir, saquinavir, raltegravir, ledipasvir, rilpivirine), tyrosine kinase inhibitors (erlotinib, dasatinib, nilotinib). Decreased AUC & C_max of tacrolimus; administer at least 2 hr before or after Lokelma.

Click to view Lokelma detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Lokelma detailed prescribing information

Storage

View Lokelma storage conditions for details to ensure optimal shelf-life.

Description

View Lokelma description for details of the chemical structure and excipients (inactive components).

Action

View Lokelma mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Other Therapeutic Products

ATC Classification

V03AE10 - sodium zirconium cyclosilicate ; Belongs to the class of drugs used in the treatment of hyperkalemia and hyperphosphatemia.

Regulatory Classification

Presentation/Packing

Form

Lokelma powd for oral susp 5 g

Packing/Price

30 × 1's (Rp3,596,034/boks)

Lokelma

sodium zirconium cyclosilicate

Manufacturer:

AstraZeneca